Dr. Xi Zhao-Wilson
Xi Zhao-Wilson, Ph.D., MBA
BioMarker Pharmaceuticals, Inc., and served as its Chief
Executive Officer and President. She is Professor at the
Chinese Academy of Preventative Medicine in Beijing.
As a Research Scientist at Stanford Medical Center, Xi conducted research focused on gene regulation in various cancers that are related to steroid hormone receptors. She has more than 15 years experience as a senior executive of startup, early stage, and established companies in the biotech industry.
She served as Corporate Development Executive at Aviron, a biopharmaceutical company that recently merged with MedImmune. She served as Founder and Chief Executive Officer of InCell, a biomedical company. She served as Senior Executive officer at Baekon, a biotech company. She serves as Chairperson of BioMarker Pharmaceuticals, Inc. Dr. Zhao-Wilson serves as Director of BioMarker Pharmaceuticals, Inc. She served as Director of Baekon.
Xi has been awarded four U.S. patents and has published numerous research articles and book chapters. She has successfully obtained research funding through an SBIR Grant from the U.S. Department of Health and Human Services and an award from the Katharine McCormick Fund. She has also lectured extensively at international research institutions including the U.S. National Institutes of Health, the Max-Planck-Institute in Germany and at numerous universities in the U.S., China, and European countries.
Her papers include The case for strategic international alliances to harness nutritional genomics for public and personal health, Grape extract protects mitochondria from oxidative damage and improves locomotor dysfunction and extends lifespan in a Drosophila Parkinson’s disease model, Neuroprotective effects of aqueous extracts of Uncaria tomentosa: Insights from 6-OHDA induced cell damage and transgenic Caenorhabditis elegans model, and Quinic acid could be a potential rejuvenating natural compound by improving survival of Caenorhabditis elegans under deleterious conditions. Her patents include Methods for testing for caloric restriction (CR) mimetics and Nutrient combinations for affecting an aging process.
Xi earned her M.S. in Molecular Genetics and Cell Biology from the Institute of Cell Biology, Chinese Academy of Sciences, and her Ph.D. in Cellular and Developmental Biology from the Ohio State University. She earned her MBA focused on international business management from the Fisher School of Business, Monterey Institute of International Studies.
View her Facebook page. Read her LinkedIn profile.